| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $164.1M | — |
| Cost of Revenue | $124.0M | +1052.9% |
| R&D Expense | $282.3M | -17.9% |
| SG&A Expense | $153.0M | +43.1% |
| Operating Income | -$395.3M | +14.2% |
| Pre-tax Income | -$375.0M | +16.2% |
| Income Tax | -$2.8M | +18.7% |
| Net Income | -$372.2M | +16.2% |
| EPS (Basic) | -$1.28 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $115.7M | +0.7% |
| Short-term Investments | $208.1M | +26.1% |
| Accounts Receivable | $69.3M | — |
| Inventory | $51.5M | +396.7% |
| Current Assets | $457.0M | +48.5% |
| Total Assets | $910.4M | +16.7% |
| Current Liabilities | $122.3M | +10.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$353.0M | +2.4% |
| Capital Expenditures | $11.1M | -50.3% |
| Investing Cash Flow | -$96.4M | +37.9% |
| Financing Cash Flow | $390.7M | -15.6% |
| Free Cash Flow | -$364.0M | +5.2% |
| +32.3% |
| EPS (Diluted) | -$1.28 | +32.3% |
| Total Liabilities |
| $200.0M |
| +2.2% |
| Stockholders' Equity | $710.4M | +21.5% |